Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and BL)~  * Any stage disease~ * Newly diagnosed disease~* Meets 1 of the following criteria for disease risk:~  * Low-risk disease, defined by 1 of the following:~    * Stage I with a single focus of disease \< 10 cm AND normal lactate dehydrogenase (LDH) level~   * Totally resected intra-abdominal disease only AND normal LDH post surgery~ * High-risk disease, defined as not meeting criteria for low-risk disease~* Measurable or nonmeasurable disease~* HIV-positive confirmed by enzyme-linked immunosorbent assay and Western blot OR by measurable HIV viral load~* No visceral Kaposi's sarcoma~PATIENT CHARACTERISTICS:~* Karnofsky performance status 40-100%~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* LVEF ≥ 50% by MUGA or echocardiogram~* Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min~* Absolute neutrophil count ≥ 1,000/mm³~* Platelet count ≥ 50,000/mm³ (unless related to lymphoma)\*~* Direct bilirubin ≤ 2.0 mg/dL OR total bilirubin ≤ 3.5 mg/dL AND direct bilirubin normal (if elevated bilirubin secondary to antiretroviral therapy)~* AST and ALT ≤ 3 times upper limit of normal~* No other malignancy within the past 5 years except curatively treated cutaneous basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or cutaneous Kaposi's sarcoma~* No other medical illness unrelated to non-Hodgkin's lymphoma, including any of the following:~  * Uncontrolled infection (including opportunistic infection)~ * Chronic renal insufficiency~ * Myocardial infarction within the past 6 months~ * Unstable angina~ * Cardiac arrhythmias other than chronic atrial fibrillation~* Patients with active hepatitis B infection are eligible provided they receive concurrent dual antiviral therapy NOTE: \*Patients with bone marrow involvement are eligible irrespective of blood count~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior therapy for this disease except for 1 of the following :~  * Seven consecutive days of steroids alone or in combination with a non-CHOP regimen necessary for patient stabilization (e.g., cyclophosphamide and steroids steroids for normalization of disease-related hyperbilirubinemia)~ * One course of CHOP or fractionated CHOP (e.g. CODOX) with or without rituximab~* No epoetin alfa or filgrastim (G-CSF) within 24 hours of study chemotherapy~* No concurrent zidovudine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Regimen A (R-CODOX-M chemotherapy) (Type: EXPERIMENTAL): Patients receive rituximab IV and doxorubicin hydrochloride IV over 15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on days 1 and 2, pegfilgrastim SC on day 3, vincristine IV on days 1 and 8, high-dose methotrexate IV over 2-4 hours on day 15, and leucovorin calcium IV beginning 24 hours after the start of methotrexate and continuing every 6 hours until level is adequate. Patients receive CNS prophylaxis of methotrexate IT, cytarabine IT, and hydrocortisone IT on day 1. Patients with high-risk disease receive an additional dose of cytarabine IT on day 3. Patients also receive G-CSF SC once daily on days 3-9. Once the methotrexate levels drops below 50 nmol/L, patients resume G-CSF SC once daily beginning on approximately day 18 and continuing until blood counts recover.
- Regimen B (rituximab and IVAC chemotherapy) (Type: EXPERIMENTAL): Patients receive rituximab IV on day 1, ifosfamide IV continuously and etoposide IV continuously over 24 hours on days 1-5, and high-dose cytarabine IV over 1-3 hours twice daily on days 1-2. Patients receive CNS prophylaxis comprising methotrexate IT and hydrocortisone IT on day 5. Patients also receive pegfilgrastim SC once 24-48 hours after completion of chemotherapy OR G-CSF SC beginning on day 6 and continuing until blood counts recover. Patients with CNS involvement (leptomeningeal and/or intraparenchymal) at diagnosis do not receive CNS prophylaxis as above. Instead, these patients receive a combination of sequential liposomal cytarabine and methotrexate IT or via an Ommaya reservoir on day 1 and then every 14 days as tolerated until completion of systemic chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).